Scarica l'app Stockscreener
225.09
3.12%
-7.25
Dopo l'orario di chiusura:
225.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$232.34
Aprire:
$230.43
Volume 24 ore:
306.52K
Relative Volume:
1.29
Capitalizzazione di mercato:
$4.49B
Reddito:
$268.09M
Utile/perdita netta:
$124.45M
Rapporto P/E:
38.58
EPS:
5.8347
Flusso di cassa netto:
$38.05M
1 W Prestazione:
+8.17%
1M Prestazione:
+10.93%
6M Prestazione:
+22.80%
1 anno Prestazione:
+110.76%
Intervallo 1D:
$221.77
$230.43
Intervallo di 1 settimana:
$198.55
$234.76
Portata 52W:
$98.89
$234.76
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
225.09 | 4.63B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $243 - GuruFocus
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
H.C. Wainwright raises Ligand Pharma price target on royalty growth By Investing.com - Investing.com Canada
Ligand Pharmaceuticals stock hits 52-week high at 228.09 USD By Investing.com - Investing.com Canada
Travere, Ligand win FDA label expansion for Filspari (TVTX) - Seeking Alpha
First approved FSGS drug gives Ligand a 9% sales royalty - Stock Titan
Free cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Cash per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
S P Trends: Will Ligand Pharmaceuticals Incorporated benefit from rising consumer demandEntry Point & Comprehensive Market Scan Reports - baoquankhu1.vn
Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
LGND Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Chart Watch: Will Ligand Pharmaceuticals Incorporated benefit from rising consumer demandTrade Volume Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
Tech Rally: Is Ligand Pharmaceuticals Incorporated being accumulated by smart money2026 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND - marketbeat.com
LGND Technical Analysis & Stock Price Forecast - Intellectia AI
LGND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is Ligand Pharmaceuticals (LGND) Still Attractive After Doubling Over The Past Year - Yahoo Finance
EBIT per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Ligand Pharmaceuticals director Kozarich sells $94k in stock By Investing.com - Investing.com Australia
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares - MarketBeat
Ligand Pharmaceuticals director Kozarich sells $94k in stock - Investing.com
Planned sales: Ligand Pharmaceuticals (LGND) director trims 467 shares - Stock Titan
Ligand Pharmaceuticals CLO sells $1m in shares By Investing.com - Investing.com India
Ligand Pharmaceuticals CLO sells $1m in shares - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares after exercising stock options - Stock Titan
Board member Todd Davis (PTHS) updates Pelthos stock grants and holdings - Stock Titan
LGND (NASDAQ: LGND) Rule 144 sales — 467 shares on three dates - Stock Titan
Insider Move: John L LaMattina Exercises Options, Realizing $185K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen - ChartMill
Ligand Pharma CLO Sells $1.03M in Stock | Transaction Details & Company BackgroundNews and Statistics - IndexBox
Ligand Pharmaceuticals director LaMattina sells $433k in shares By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director LaMattina sells $433k in shares - Investing.com
Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares - Stock Titan
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
CLO Sells LGND 5,000 Shares for $1.0 Million - AOL.com
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):